Reason for request
The actual benefit of UMATROPE in adults with GH deficiency remains moderate.
The actual benefit provided by UMATROPE in children with SHOX gene deficiency remains moderate.
The actual benefit of UMATROPE in children with GH deficiency remains substantial .
The actual benefit of UMATROPE in children born small for gestational age with a birth weight and/or height < -2 SD, who have failed to show catch-up growth (growth velocity < 0 SD during the last year) by 4 years of age or later and whose growth retardation (current height) is below or equal to -3 SD and the adjusted parental height < -1 SD remains low.